纤维蛋白原浓缩物对高危心脏手术术中出血患者术中失血量的影响:一项随机临床试验
该随机、安慰剂对照、双盲临床试验在荷兰Isala Zwolle医院2011年2月至2015年1月纳入120例择期高危心脏手术且术中出血(5分钟内胸腔引流量60-250 mL)患者,随机接受单次静脉纤维蛋白原浓缩物(n=60)或安慰剂(n=60),目标为输注后血浆纤维蛋白原水平达2.5 g/L。主要终点为停体外循环后至关胸期间的失血量,纤维蛋白原组中位失血50 mL(IQR 29-100)vs 对照组70 mL(IQR 33-145),P=0.19,绝对差异20 mL(95%CI -13至35)。结论认为纤维蛋白原浓缩物与安慰剂相比术中失血量无显著差异。
要点
- 择期高危心脏手术术中出血(5分钟内胸腔引流量60-250 mL)患者,单次静脉纤维蛋白原浓缩物目标血浆水平2.5 g/L,未能显著减少术中失血。
- 主要终点中位失血量:纤维蛋白原组50 mL(IQR 29-100)vs 安慰剂组70 mL(IQR 33-145),P=0.19,绝对差异20 mL(95%CI -13至35)。
- 30天安全性事件:卒中或短暂性脑缺血发作6例(纤维蛋白原组4例),心肌梗死4例(纤维蛋白原组3例),死亡2例(均在纤维蛋白原组)。
- 其他安全性事件:肾功能不全或衰竭5例(纤维蛋白原组3例),再次开胸9例(纤维蛋白原组4例)。
- 该研究为单次给药方案,目标纤维蛋白原水平2.5 g/L,不能外推至其他剂量或给药策略。
适用人群与场景
- 择期高危心脏手术患者,包括冠状动脉旁路移植联合瓣膜修复或置换、多瓣膜置换、主动脉根部重建、升主动脉或主动脉弓重建。
- 术中出血定义为5分钟内从胸腔吸引的血液体积在60至250 mL之间。
- 研究在荷兰Isala Zwolle医院开展,时间为2011年2月至2015年1月。
处置流程与药物剂量
- 单次静脉给予纤维蛋白原浓缩物(n=60)或安慰剂(n=60),目标为输注后血浆纤维蛋白原水平达到2.5 g/L。
- 主要终点评估时间为停体外循环后至关胸期间的失血量(mL)。
研究设计与关键结果
- 随机、安慰剂对照、双盲临床试验,纳入120例患者(平均年龄71岁,标准差10;女性37例,占31%),冠状动脉旁路移植联合瓣膜手术占72%,平均体外循环时间200分钟(标准差83分钟)。
- 主要终点:纤维蛋白原组中位失血量50 mL(IQR 29-100)vs 对照组70 mL(IQR 33-145),P=0.19,绝对差异20 mL(95%CI -13至35)。
- 30天安全性事件:卒中或短暂性脑缺血发作6例(纤维蛋白原组4例);心肌梗死4例(纤维蛋白原组3例);死亡2例(均在纤维蛋白原组);肾功能不全或衰竭5例(纤维蛋白原组3例);再次开胸9例(纤维蛋白原组4例)。
证据类型、等级与局限
- 证据类型:随机、安慰剂对照、双盲临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在高危心脏手术术中出血患者中,单次静脉纤维蛋白原浓缩物目标血浆水平2.5 g/L与安慰剂相比术中失血量无显著差异,原文结论未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Fibrinogen concentrate might partly restore coagulation defects and reduce intraoperative bleeding.
OBJECTIVE: To determine whether fibrinogen concentrate infusion dosed to achieve a plasma fibrinogen level of 2.5 g/L in high-risk cardiac surgery patients with intraoperative bleeding reduces intraoperative blood loss.
DESIGN, SETTING, AND PARTICIPANTS: A randomized, placebo-controlled, double-blind clinical trial conducted in Isala Zwolle, the Netherlands (February 2011-January 2015), involving patients undergoing elective, high-risk cardiac surgery (ie, combined coronary artery bypass graft [CABG] surgery and valve repair or replacement surgery, the replacement of multiple valves, aortic root reconstruction, or reconstruction of the ascending aorta or aortic arch) with intraoperative bleeding (blood volume between 60 and 250 mL suctioned from the thoracic cavity in a period of 5 minutes) were randomized to receive either fibrinogen concentrate or placebo.
INTERVENTIONS: Intravenous, single-dose administration of fibrinogen concentrate (n = 60) or placebo (n = 60), targeted to achieve a postinfusion plasma fibrinogen level of 2.5 g/L.
MAIN OUTCOMES AND MEASURES: The primary outcome was blood loss in milliliters between intervention (ie, after removal of cardiopulmonary bypass) and closure of chest. Safety variables (within 30 days) included: in-hospital mortality, myocardial infarction, cerebrovascular accident or transient ischemic attack, renal insufficiency or failure, venous thromboembolism, pulmonary embolism, and operative complications.
RESULTS: Among 120 patients (mean age; 71 [SD, 10] years, 37 women [31%]) included in the study, combined CABG and valve repair or replacement surgery comprised 72% of procedures and had a mean (SD) cardiopulmonary bypass time of 200 minutes (83) minutes. For the primary outcome, median blood loss in the fibrinogen group was 50 mL (interquartile range [IQR], 29-100 mL) compared with 70 mL (IQR, 33-145 mL) in the control group (P = .19), the absolute difference 20 mL (95% CI, -13 to 35 mL). There were 6 cases of stroke or transient ischemic attack (4 in the fibrinogen group); 4 myocardial infarctions (3 in the fibrinogen group); 2 deaths (both in the fibrinogen group); 5 cases with renal insufficiency or failure (3 in the fibrinogen group); and 9 cases with reoperative thoracotomy (4 in the fibrinogen group).
CONCLUSIONS AND RELEVANCE: Among patients with intraoperative bleeding during high-risk cardiac surgery, administration of fibrinogen concentrate, compared with placebo, resulted in no significant difference in the amount of intraoperative blood loss.
TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01124981 and EudraCT No: 2009-018086-12.
参考来源
- Bilecen S, de Groot JA, Kalkman CJ, et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High-Risk Cardiac Surgery: A Randomized Clinical Trial. JAMA. 2017. PMID: 28241354. doi:10.1001/jama.2016.21037
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。